Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric aprepitant pharmacokinetics and safety study for prevention of postoperative nausea and vomiting
2011-006006-27Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of aprepitant in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Merck & Co. Primary endpoints: Cmax, Tmax and 3 more. Started Sep 2012; status: completed.
02
Drugs
aprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on 2011-006006-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006006-27.